Strength Seen in ResMed (RMD): Can Its 3.8% Jump Turn into More Strength?

Company Overview - ResMed (RMD) shares increased by 3.8% to close at $213, following notable trading volume, despite a previous 11.7% loss over the past four weeks [1] - The company is set to release its fiscal 2025 third-quarter financial results on April 23, which has generated investor optimism [2] Financial Performance Expectations - ResMed is expected to report quarterly earnings of $2.36 per share, reflecting a year-over-year increase of 10.8%, with revenues projected at $1.28 billion, up 7.3% from the same quarter last year [3] - The consensus EPS estimate has been revised marginally lower over the last 30 days, indicating a potential negative trend in earnings estimate revisions [4] Market Position and Competitors - ResMed is part of the Zacks Medical - Products industry, where AdaptHealth Corp. (AHCO) also operates, closing 5.4% lower at $9.56, with a -3.6% return over the past month [4] - AdaptHealth's consensus EPS estimate remains unchanged at $0.01, representing a 50% decrease from the previous year [5]